Interaction Checker
No Interaction Expected
Dolutegravir/Lamivudine (DTG/3TC)
Buprenorphine
Quality of Evidence: Very Low
Summary:
Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Norbuprenorphine, an active metabolite, can further undergo glucuronidation (via UGT1A3 and UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. Coadministration of buprenorphine and lamivudine had no significant effect on buprenorphine pharmacokinetics or NRTI concentrations when compared to control data.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.